MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lungcan.2023.107379

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2023

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.

Falchero Lionel, Guisier Florian, Darrason Marie, Boyer Arnaud, Dayen Charles, Cousin Sophie, Merle Patrick, Lamy Régine, Madroszyk Anne, Otto Josiane, Tomasini Pascale, Assoun Sandra, Canellas Anthony, Gervais Radj, Hureaux José, Le Treut Jacques, Leleu Olivier, Naltet Charles, Tiercin Marie, Van Hulst Sylvie, Missy Pascale, Morin Franck, Westeel Virginie, Girard Nicolas

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Small cell lung cancer (SCLC) has a tendency towards recurrence and limited survival. Standard-of-care in 1st-line is platinum-etoposide chemotherapy plus atezolizumab or durvalumab,based on landmarkclinical trials.

METHODS

IFCT-1905 CLINATEZO is a nationwide, non-interventional, retrospectivestudy of patients with extensive-SCLC receivingatezolizumab plus chemotherapy as part of French Early Access Program. Objectives were to analyse effectiveness,safetyand subsequent treatments.

RESULTS

The population analyzed included 518 patients who received atezolizumabin 65 participating centers. There were 66.2% male,mean age was 65.7 years; 89.1% had a performance status (PS) 0/1 and 26.6% brain metastases. Almost all(95.9%) were smokers. Fifty-five (10.6%) received at least 1 previous treatment. Median number of atezolizumab injections was 7.0 (range [1.0-48.0]) for a median duration of 4.9 months (95% CI 4.5-5.1). Atezolizumab was continued beyond progression in 122 patients (23.6%) for a median duration of 1.9 months (95% CI: [1.4-2.3]). Best objective response was complete and partialin 19 (3.9%) and 378 (77.1%)patients. Stable diseasewas observed in 50 patients (10.2%). Median follow-up was30.8 months (95% CI: [29.9-31.5]). Median overall survival (OS), 12-, 24-month OS rates were 11.3 months (95% CI: [10.1-12.4]), 46.7% (95% CI [42.3-50.9]) and 21.2% (95% CI [17.7-24.8]). Median real-world progression-free survival, 6-, 12-month rates were 5.2 months (95% CI [5.0-5.4]), 37.5% (95% CI [33.3-41.7]) and 15.2% (95% CI [12.2-18.6]). For patients with PS 0/1, median OS was 12.2 months (95% CI [11.0-13.5]). For patients with previous treatment, median OS was 14.9 months (95% CI [10.1-21.5]). Three-hundred-and-twenty-six patients(66.4%) received subsequent treatment and27 (5.2%) were still underatezolizumabat date of last news.

CONCLUSIONS

IFCT-1905 CLINATEZO shows reproductibility, in real-life,ofIMpower-133survival outcomes, possibly attributed to selection of patients fit for this regimen, adoption of pragmatic approaches,including concurrent radiotherapy and treatment beyond progression.

Для цитирования: Falchero Lionel, Guisier Florian, Darrason Marie, Boyer Arnaud, Dayen Charles, Cousin Sophie, Merle Patrick, Lamy Régine, Madroszyk Anne, Otto Josiane, Tomasini Pascale, Assoun Sandra, Canellas Anthony, Gervais Radj, Hureaux José, Le Treut Jacques, Leleu Olivier, Naltet Charles, Tiercin Marie, Van Hulst Sylvie, Missy Pascale, Morin Franck, Westeel Virginie, Girard Nicolas. Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.. Lung cancer (Amsterdam, Netherlands). 2023. DOI: 10.1016/j.lungcan.2023.107379.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.